Rapport Therapeutics opened lower at $26.76, compared with its previous close of $27.02. In the last trading session, the stock traded between $25.45 and $26.90. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Rapport Therapeutics is now worth
$ 124.26
Giving a profit of
$ 24.26 (24.26%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 14 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.17 (-4.34%)
Day High
$26.90
Day Low
$25.45
Day Open
$26.76
Prev Close
$27.02
Volume
4,75,624
1W Return
-0.27%
1M Return
-14.50%
3M Return
-47.11%
6M Return
-32.75%
1Y Return
1.36%
Fundamentals
Market Cap ($ Mn)
1,532
PE Ratio
-
PB Ratio
5.53
PEG Ratio
-
ROE
-30.11%
ROCE
-33.15%
EPS (TTM)
-
Investment Returns
1 Week
-0.27%
1 Month
-14.50%
3 Months
-47.11%
6 Months
-32.75%
9 Months
-6.49%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
UBS maintains Buy on Rapport Therapeutics, cuts price target to $64
UBS analyst Joon Lee maintains a Buy rating on Rapport Therapeutics. Price target lowered from $71 to $64. Rating action reflects updated valuation metrics for the biotech firm.
7 days ago
21Oct
Jones Trading maintains Buy on Rapport Therapeutics, hikes PT to $82
Jones Trading maintains Buy rating on Rapport Therapeutics. Price target raised from $50 to $82. Analyst Justin Walsh leads the coverage update.
22 days ago
21Oct
Wells Fargo maintains Overweight on Rapport, cuts price target to $50
Wells Fargo maintains Overweight rating on Rapport Therapeutics. Price target lowered from $51 to $50. Analyst Benjamin Burnett issued the rating update.
22 days ago
21Oct
Guggenheim maintains buy on Rapport Therapeutics, raises target to $70
Guggenheim maintains a Buy rating on Rapport Therapeutics. Price target increased from $65 to $70. Analyst Delma Caiati issued the revised recommendation.
22 days ago
20Oct
HC Wainwright reiterates Buy on Rapport Therapeutics with $66 target
HC Wainwright analyst Douglas Tsao reiterates Buy rating on Rapport Therapeutics. Price target maintained at $66 per share. Analyst confidence remains unchanged from prior assessments.
23 days ago
20Oct
Rapport Therapeutics stock up 36% as Phase 2 trial meets endpoint
Rapport Therapeutics stock rose 36.02% to $38.90 in premarket trading. Phase 2 trial of RAP-219 met primary endpoint with 3.1-point YMRS improvement vs placebo. Drug showed favorable tolerability with no severe treatment-emergent adverse events. Company holds $436.1 million in cash to fund operations into second half of 2029.
